EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Q32 Bio Inc (QTTB) fair value: what the stock is really worth

As of Sep 23, 2026: fair value of Q32 Bio Inc $7.85, price $9.56, upside -17.9%, quality 70 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? Yes
  3. Add to watchlist

Healthcare · US · ISIN US7469641051

QB Q32 Bio Inc logo Some data Sep 23, 2026

Q32 Bio Inc

QTTB · US

Overvalued / MonitorQuality is not strong enough to offset the price risk.

!Fair value $7.85 · Overvalued (−18%)
✓Quality 70/100
!Mixed Growth (revenue 5y +81.9 %/yr)
✓Highly profitable · 62.9% net margin (TTM)
!Low debt · negative free cash flow
✓Ranks above peers (9/12)
✓Wide moat 90/100
!Evidence only medium, so the estimate is less certain
!Weak on valuation: 10 out of 100
Watch Q32 Bio Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$156.78 $1.36 Fair Value $7.85 Jun 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.

How to read this chart

60‑month range $1.36 – $156.78 · fair‑value band $6.13 – $9.58 · the $9.56 price screens above the $7.85 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 23, 2026.

Follow Q32 Bio in your weekly email

Every Wednesday you see whether Q32 Bio is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction.

Show more

Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human anti"interleukin-7 receptor alpha antagonist monoclonal antibody which completed Phase 2a clinical trials, designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic dermatitis and alopecia areata. It also develops ADX-096, a C3d mAb " CR1 fusion protein for use in ophthalmologic indications, as well as other C3d mAb fusions and nanobodies designed for tissue-targeted complement inhibition and a range of other indications. The company was founded in 2017 and is based in Waltham, Massachusetts.

Stock analysis

Q32 Bio Inc (QTTB) currently trades at $9.56, while our model-based Fair Value estimate is $7.85, implying the stock looks roughly 21.7% overvalued today.

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of $46.54 per share, and 9 of the 15 models we run sit above the $9.56 price.

Bear case: the Asset-Based group reads lowest at $0.9500, and 6 of the 15 models stay below the price. Evidence for this calculation is medium.

Scenario range: $6.13 (bear) to $9.58 (bull), the price of $9.56 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 70/100 (solid quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Q32 Bio Inc reported revenue of $53.7M in FY2025 versus $34.0M in FY2021, a compound +12.1%/yr. Reported net income was $29.8M in FY2025.

Key figures

Market cap $312M · P/E ratio 3.0 · P/S ratio 1.69 · EPS (TTM) $3.14 · Net margin 55.5% · Return on equity 72.1% · Return on assets (EBIT) −51.1% · Operating margin 39.9%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 51 out of 100 (low confidence).

What moves the price

The share trades about 55% below its 52-week high and 428% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −18%, QTTB screens richer than that median.

Fair Value models

Bear $6.13 Fair Value $7.85 Bull $9.58
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then ($2.31 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
EPV $5.59 $6.15 $6.62 74
Owner Earnings $14.86 $29.19 $55.77 70
ROIC Compounder $5.59 $6.15 $6.62 70
All 15 models by family
DCF Models
Owner Earnings $14.86 $29.19 $55.77 70
Earnings-Based
Graham-Dodd $6.81 $47.50 $66.67 61
Lynch FV $24.54 $35.06 $45.58 59
PEG = 1.0 $24.54 $35.06 $45.58 55
EPV $5.59 $6.15 $6.62 74
Multiples
P/E Multiple $16.53 $22.04 $27.55 63
P/S Multiple $4.74 $6.32 $7.90 58
P/B Multiple $4.76 $6.35 $7.94 55
EV/EBIT $8.74 $11.16 $13.57 66
EV/EBITDA $7.61 $9.64 $11.67 67
EV/Revenue $5.30 $6.92 $8.55 54
Asset-Based
NCAV (Graham) $0.7100 $0.9500 $1.41 54
Economic Profit
Residual Income $7.11 $12.18 $270.00 56
ROIC Compounder $5.59 $6.15 $6.62 70
Growth Earnings
Growth-Adj P/E $32.58 $46.54 $60.50 65

Open the full fair value analysis →

Notify me when QTTB reaches fair value

Put QTTB on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 70/100

Of which business quality 64 · Market factors (momentum, volatility) 64

Profitability 93
Margins and returns on capital today
Quality Growth 100
Are margins and returns improving?
Cashflow 0
Earnings quality: real cash, not paper profit
Fin. Strength 98
Balance sheet, leverage, solvency risk
Investment 100
Disciplined investing over empire-building
Low Volatility 50
Calm price path (market factor)
Momentum 69
Price trend over the last 3–12 months (market factor)
52W Momentum 70
Distance to the 52-week high (market factor)
Net Issuance 0
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 57/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+100.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+81.9%
Start year 2020 (pandemic)
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+39.1%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−4,821.0% (2020) → 31.5% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no profitable base year
not computed

QTTB screens 22% overvalued. Compare with Vertex Pharmaceuticals Incorporated →

Compare Q32 Bio Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 649 stocks

Beats the industry median on 9/12 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 70 · Top 25%
Fair Value upside −18% · Above median
Profitability
Return on equity (TTM) 72% · Top 25%
Return on assets 15% · Top 25%
Net margin (TTM) 63% · Top 25%
Operating margin (TTM) 40% · Top 25%
Growth and dividend
Revenue growth 0% · Above median
Balance sheet
Debt / equity 0.08× · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/E (TTM) 3.0× · Cheapest 25%
P/B 7.42× · Priciest 25%
P/S (TTM) 5.80× · Pricier than median
EV/EBITDA 12.2× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)10 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)100 · sector 0
HEALTH (low debt)96 · sector 97
DIVIDEND (yield)0 · sector 23

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $516.34 $567.97 +10%
Regeneron Pharmaceuticals, Inc REGN $801.82 $1,252 +56%
argenx SE ARGX $963.79 $918.60 −5%
Samsung Biologics Co 207940 1,366,000 KRW 1,502,600 KRW +10%
CSL Limited CSL A$179.12 A$197.03 +10%
Alnylam Pharmaceuticals, Inc ALNY $251.65 $218.36 −13%
Royalty Pharma plc RPRX $58.52 $24.22 −59%
BeOne Medicines AG 6160 HK$218.20 HK$169.72 −22%
Celltrion, Inc 068270 177,400 KRW 74,519 KRW −58%
BioNTech SE BNTX $100.87 $63.62 −37%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Q32 Bio Inc · Fair Value
$7.85 −22%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Q32 Bio Inc Fair Value". https://www.fairvalue-calculator.com/stock/QTTB

Frequently asked questions

Is Q32 Bio Inc (QTTB) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of $7.85 versus a price of $9.56, about −18% upside (overvalued).
What is the fair value of QTTB?
Our model-based fair value for Q32 Bio Inc is $7.85 (as of Sep 23, 2026), built from audited fundamentals. The current price: $9.56.
What is the quality score of QTTB?
Q32 Bio Inc has a Quality Score of 70/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Q32 Bio Inc (QTTB)?
Our model-based price target is the fair value of $7.85 (as of Sep 23, 2026) from 15 valuation models. Cautious scenario $6.13, optimistic scenario $9.58. It is a calculation from audited fundamentals, not an analyst target.
What is the Q32 Bio Inc stock forecast for 2026?
Our models put fair value at $7.85, about −18% upside versus a price of $9.56 (overvalued). Cautious scenario $6.13, optimistic scenario $9.58. The calculation is refreshed regularly with new filings.
What is the revenue of Q32 Bio Inc (QTTB)?
Q32 Bio Inc reported trailing-twelve-month revenue of about $53.7M (latest available figure, as of Sep 23, 2026).
What is the intrinsic value of Q32 Bio Inc (QTTB)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Q32 Bio Inc it is $7.85 per share (as of Sep 23, 2026), against a price of $9.56. It is the blended result of 15 valuation models (cash flow, earnings, asset, dividend).
Is Q32 Bio Inc stock overvalued or undervalued in 2026?
As of Sep 23, 2026, QTTB trades above its calculated fair value: price $9.56, fair value $7.85, a gap of about −18% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of QTTB?
No. The price is what the market pays today ($9.56); the fair value is what the company's own numbers justify ($7.85). For Q32 Bio Inc the two are $1.71 per share apart. That gap is exactly why we show both numbers side by side.
How much is Q32 Bio Inc worth?
The market values Q32 Bio Inc at about $312M (market capitalisation, as of Sep 23, 2026). Per share that is $9.56; our models calculate a fair value of $7.85 per share.
What do the bullish and bearish scenarios say about QTTB?
Our models span a range for Q32 Bio Inc: cautious scenario $6.13, base $7.85, optimistic $9.58 per share (as of Sep 23, 2026, price $9.56). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of QTTB?
Q32 Bio Inc trades at a price-to-earnings ratio of 3.0 (as of Sep 23, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $7.85 is built from several models across several years. Other multiples: P/B 7.4, P/S 5.8, EV/EBITDA 12.2.
How solid is the balance sheet of Q32 Bio Inc (QTTB)?
Balance-sheet figures for Q32 Bio Inc (as of Sep 23, 2026): return on equity 72.1%, debt of 0.08 per unit of equity. They feed the Quality Score of 70/100, which measures business quality independently of the share price.
How far is QTTB from its 52-week high?
Q32 Bio Inc trades at $9.56, about 55% below its 52-week high of $21.38 and 428% above the low of $1.81 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of $7.85 is for.
Which stocks are comparable to Q32 Bio Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Q32 Bio Inc stock attractive at the current price?
The data as of Sep 23, 2026: price $9.56, calculated fair value $7.85 (−18%), Quality Score 70/100, from 15 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of QTTB calculated?
We run Q32 Bio Inc through 15 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $7.85, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Q32 Bio Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Q32 Bio Inc (QTTB)?
The closing price on Sep 23, 2026 was $9.56. Our model-based fair value is $7.85, about −18% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Q32 Bio Inc right now?
A high-quality business (quality 70/100), yet the market already pays well above fair value. Quality at a full price, with little margin of safety. The price sits in the upper half of our model range, so the margin of safety is thin. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.

Key figures of Q32 Bio Inc

How large is the market capitalisation of Q32 Bio Inc (QTTB)?
The market capitalisation of Q32 Bio Inc is $312M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Q32 Bio Inc (QTTB)?
The price-to-sales ratio of Q32 Bio Inc is 1.69 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Q32 Bio Inc (QTTB)?
Earnings per share at Q32 Bio Inc are $3.14 (price ÷ EPS = P/E 3.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Q32 Bio Inc (QTTB)?
The net margin of Q32 Bio Inc is 55.5% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Q32 Bio Inc (QTTB)?
The return on equity (ROE) of Q32 Bio Inc is 72.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Q32 Bio Inc (QTTB)?
On an EBIT basis the return on assets of Q32 Bio Inc is −51.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Q32 Bio Inc (QTTB)?
The operating margin of Q32 Bio Inc is 39.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How much free cash flow does Q32 Bio Inc (QTTB) generate?
The free cash flow of Q32 Bio Inc is −$33.5M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Q32 Bio Inc (QTTB) hold?
Q32 Bio Inc holds more cash than debt, $33.0M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Q32 Bio Inc in the live analysis

One click puts Q32 Bio Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.